Bionpharma Inc. announced the approval of the generic drug atovaquone, allowing the company to enter new markets and strengthen its portfolio of accessible therapies for blood and brain parasites. The clearance is expected to improve supply chain stability for manufacturers and reduce costs for patients requiring oral treatments with short shelf lives.